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Radiation-induced cancer of bone, liver, and lung has been a promi-
nent harmful side-effect of medical applications of alpha emitters. In
recent years, however, the potential use of antibodies labeled with
alpha emitting radionuclides against cancer has seemed promising be-
cause alpha particles are highly effective in cell killing. High close
rates at high LET, effectiveness under hypoxic conditions, and minimal
expectancy of repair are additional advantages of alpha emitters over
antibodies labeled with beta emitting radionuclides for cancer therapy.
Cyclotron-produced astatine-211 (21aAt) and natural bismuth-212
(2_ZBi) have been proposed and are under extensive study in the
United States and Europe. Radium-223 (a23Ra) also has favorable
properties as a potential alpha emitting label, including a short-lived
daughter chain with four alpha emissions. The radiation dosimetry or"
internal alpha emitters is complex due to nonuniformly distributed
sources, short particle tracks, and high relative specific ionization. The
variations in dose at the cellular level may be extreme. Alpha-particle
radiation dosimetry, therefore, must involve analvsis of statistical
ener_, deposition probabilities for cellular level targets. It must also
account full), for nonuniform distributions of sources in tissues, source-
target geometries, and particle-track physics.
INTRODUCTION
Alpha particles are energetic, positively charged helium nuclei






per nucleon (or packing fraction) has fallen below a critical value.
.... Alpha-particle decay is typical of many of the heaviest known radio-
nuclides, both natural and man-made. For example, natural thorium-
228 decays by alpha emission to radium-224, and cyclotron-prods.iced
astatine-211 decays by alpha emission to bismuth-207. Most alpha
emitters in the environment are members of the natural uranium-238
and thorium-232 decay series. Others, such as plutonium-238, are
produced during nuclear reactions. The physical half-lives of alpha
emitters are constants ranging from milliseconds to billions of years,
depending on the radionuclide.
The energy released to matter by alpha particles emitted from atomic
nuclei is distributed along very, short (30-70 _m in tissues), straight
tracks having a high ionization density. This distribution is very,
different from tracks produced by beta particles and gamma rays.
The characteristics of energy deposition by alpha particles in matter
are important in assessing their potential to produce biological damage.
The radiation dosimetry for alpha emitter_ must address energy distri-
bution on a microscopic scale to account for the probability of irradiat-
ing single cells. A cellular level approach to alpha-particle dosimetry
is key to understanding why alpha particles are considerably more
effective per unit energy imparted in producing radiobiological effects
than beta or gamma radiation.
This paper covers fundamental concepts of alpha-particle dosimetry
and microdosimetry and the radiobiological significance of alpha-
particle energy deposition in small sites. It also briefly reviews the
historical applications of alpha emitters in medicine and the potential
for new applications in the treatment of disease.
HISTORICAL PERSPECTIVE
Shortly after natural radioactivity was discovered in 1896 by
Becquerel, Soddy and Rutherford showed that naturally radioactive
substances were mL,ctures of several isotopes. The}, separated radium-
2__4 (aZO'Ra) from thorium in 1902. This radionuclide with its abundant
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alpha emissions was used in dermatology, for skin lesions and ['or treat-
ment of rheumatic diseases (1). Radium-224 was first used in 1912 for
treatment of ank),losing spondylitis (with limited success) and later for
tl.iberculosis (not effective).
Bottled radium solutions as the stimulant. "Radithor" were prescribed
to cure almost an), ailment. Radium appeared to ease the pain associ.
ated with inflammation, stiffening, and crookedness of the vertebra/
column in ankylosing spondylitis patients and to ease the movement
of joints in the treatment of rheumatoid synovitis.
Death resulted from acute radiation syndrome in early patients
administered large oral doses of ZZ6Ra solution, and internal applica-
tions were discontinued for a period of time. The intravenous injec-
tion of ZZ4Ra against rheumatic disease began again in France in 1922,
in England in 1946, and in Germany in 1947. The use of ZZ4Ra in
treatment of ankylosing spondylitis resumed in 1964 in France. Favor-
able results encouraged further use of ZZ4Ra against rheumatoid arthri-
tis (2). Radium-224 is still used for treating adult spondylitic patients
in German),, but current doses are considerably, smaller than those
given earlier.
The major late effects of zZL'Ra have been bone cancers induced by
the bone-surface-seeking radium and radioactive daughter products.
A long-term follow-up of ZZ6Ra watch dial painters also showed malig-
nant bone tumors and carcinomas of the mastoid:, and paranasal
sinuses.
,t,
Thorium colloid (Thorotrast) containing thorium-232 and decay-series
daughter products was given as a contrast medium for radiographic
examinations (such as cerebral angiography), primarily in Germany,
starting as early as about 1920 and continuing until recently. Liver
tumors and leukemia have been the most significant late side-elTects
of Thorotrast (3). Recent network television documentaries have des-




POTENTIAL APPLICATIONS AGAINST CANCER
Ironically, alpha emitters now promise to be highly effcctivu against
cancer when administered as immunoconjugates (4-8). Among the
advantages of alpha emitting radionuclides over other possible ch{_iccs
are:
1. higher close rates with high linear energy tr_tnsl'cr
(LET), and therefore
2. more efficient cell killing
3. nonreparable cellular damage
4. effectiveness under hypoxic conditions
5. more selective irradiation of tumor cells and sparin,,
of normal tissues.
The last advantage has been described by H'umm, Chin, and Cobb (9)
as a "geometric enhancement factor" favoring the inactivation oi" cells
by alpha emitters when compared to beta emitters.
Some of the disadvantages of alpha emitters have been discussed in
the literature. Many alpha emitters have short half-lives, limiting their
application in medicine, and are expensive to produce. As labeled
immunoconjugates, their high dose rates in solution can lead to
extensive physical damage of the protein and a decrease of immuno-
specificity during preparation or before cancer cells are targeted.
Radiation safety aspects of handling alpha emitters may also be
somewhat more complicated than for pure beta and beta-gamma emit-
ters. The limited range of alpha particles could make them ineffective
in the treatment of some solid tumors if tumor cell labeling is not
uniform.
Alpha emitting immunoconjugates of potential medical application




injection in mice (7,8), to selectively ablate B-cell lymphocytes in mice
(5), and to increase the median survival time of mice with T-cell lym-
phoma (4). Human trials are expected in the near future.
Most alpha emitters are isotopes of elements that are taken up Dy
bone during growth and remodeling. Short-lived alpha emitters on
bone surfaces could lead to induction of bone cancer. However, bone
cancer should not be of concern as a secondary toxicological late
effect of an alpha labeled immunoconjugate for the following reason"
a tightly conjugated alpha emitter should express the biological reten-
tion, distribution, and clearance of the host protein rather than that
of a free, bone-seeking radionuclide. Immunoconjugates targeting
cancer cells should effectively deliver the alpha emitter to those cells,
whereas immunoconjugates not finding tumor cells should be rapidly
: excreted from the body. The immunoconjugate would not be taken
up by bone. Radioactive daughter products, however, may break away
from the protein during transformation and recoil, anti may therefore
behave as free ions in biological media.
'K
CHARACTERISTICS OF ALPHA-PARTICLE TRACKS
Alpha particles emitted from the atomic nuclei of unstable radio-
nuclides have an exit energy of 1.8 to 11.6 MeV, depending on the
radionuclide. Energies, half-lives and yields of some important alpha
emitters are given in Table 1. Some alpha emitters exhibit "branching
decay." For example, bismuth-212 decays 3,:;% of the time by alpha
emission and 66% of the time by beta emission. The beta-decay
daughter product polonium-212 then decays by alpha emission to
stable lead-208. Thus, there are effectively one 6.07 MeV alpha
particle and two 8.78 MeV alpha particles from eve_, three decays or"
bismuth-212.
Alpha particles are helium nuclei ejected from the nuclei oi"
unstable heavy elements with initial kinetic energies typically in the
range of about 4 to 8 MeV (Table 1). As heliuim nuclei, they carry
a positive charge of 2 and interact strongly with atomic electrons as
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TABLE 1. ENERGY, HALF-LIFE, YIELD," AND DAUGHTER
PRODUCT OF SOME COMMON ALPHA EMITTERS
Radionuclide Mean c_ Physical Yield" Daughter
Product Energy Half-Life (%)
(MEV)
Thorium-232 3.98 14.1 billion y 100 radium:228
Uranium-238 4.17 4.51 billion y 100 thorium-234
Radium-226*" 4.78 1,600 y 100 radon-222
Plutonium-239 5.14 24,400 y 100 uranium-235
Polonium-210 5.30 138 d 100 lead (stable)
Americium-241 5.47 458 d 100 neptunium-237
Plutonium-238"* 5.48 86 v 100 uranium-234
Radium-224"* 5.67 3.64 d 100 radon-220
Radium-223"* 5.67 11.43 d 100 radon-219
Actinium-225 5.79 10.0 d 100 francium-221
Astatine-211 5.87 7.21 h 42 bismuth-207
branching decay, electron
I_ " capture 58 polonium-211
-polonium-211 7.45 0.5 s 99 lead (stable)
Bismuth-212** 6.07 60.6 m 34 thallium-208
branching decay,
beta 66 pc lonium-..l_"_
--.polonium-212 8.78 0.3 ,zs 100 lead (stable)
* Yield = percentage of ali decays resulting in alpha emission.
** Applications in medicine: Radium-226 for brachytherapy
sources, plutonium-238 for battery, packs (artificial hearts),
rad" _"lum-2_a for immunoconjugates (also astatine-211
actinium-225, and bismuth-212).
they pass through matter, producing ionizations and excitations and
giving ,lp energy in the process. On average, about 34 eV arc
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expended for each ion pair produced; thus, many atoms or molecules
are ionized during the interaction of alpha particles with matter. The
particle "track" is a pattern of dense ionization events that can be
directly associated with ew.'ntual subcellular biological damage.
A portion of a 6 MeV alpha-particle track is shown in Figure 1.
['he x's represent primary ionizations, and the solid dots represent
secondary ionizations from electrons (delta rays) that have been ener-
gized by the alpha particle. Alpha particles follow straight part;s,
whereas secondary electrons radiating from the dense central core of
the track follow a somewhat random path in the forward direction.
The effective radius of the track is about 60 nm (0.06 v,m). The range
of the particle is .a function of energy and stopping material. An
empirical formula for estimating the range of alpha particles in s_lt
tissue was derived by Polig (10) from experimental data:
Ro = 3.62E1"43 (1)
where: R o is the alpha particle range in micrometers (_m), and E is i,,;
initial kinetic energ3, in MeV. 1
The approximate alpha-particle range in tissue relative to the
range in air may be derived from the Bragg-Kleeman rule (11):
Rm/Rai r = (/,air/m)(Am/Aair) ' (2)
where R mis the rat:ge of the alpha particle in tissue, Rai r is the range
in air, f is the density of air or tissue, and A, is the et'fective atomic
weieht of tissue or air. The effective atomic weieht of an absorbin,
medium is determined from the relationship:
(Ae_,_,)'l/2 = f3/(A,.i)3/a + fj(A?) 1/_- -t- .... (3)
where fl is the fraction by weight of atom 1, k 1 is the atomic weight
of atom 1, etcetera, for the different atoms comprising each substance.
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HGURE 1. Computer-generated segment of hypothetical charged-
particle track. Crosses represent primary, ionizations along central
core of track, and dots represent secondat3' ionizations forming delta-
ray secondaries.
The relative specific ionization (dE/dx) per unit track length
increases according to the familiar Bragg curve (Fig. 2), and more
energy is expended near the end of the alpha particle track than at
tl'.e beginning. The value dE/dx may increase by a factor of 2.5 to 3.0
near the end of the track. The mean linear energy transfer (LET) is
the mean energy imparted per unit track length. LET, aiso known as
collision stopping power, can be defined in terms of dE/dx, where tiE
is the mean energy lost by a charged particle along a distance dx of
its trajectory. For example, a 5.5 MeV particle traveling 38/.Lm in soft
tissue would have an LET of 5,500 keV/38 _m = 145 keV/_m. Alpha
particles have high LET, whereas beta particles have low LET. In
general, the LET increases with particle charge and decreases with
particle velocity.
"TARGET" SITF.,S
Alpha particles impart ener_ to ali matter alo_,g the path. The
"target" is the biologically important solid volume of mass m inter-
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FIGURE 2. Bragg curve for alpha particles.
kidney, etc.), tumor or micrometastasis, clump of cells or a single cell,
or any solid volume considered for purposes of radiation dosimetry.
It could also be the nucleus of a cell or a small,er volume within the
nucleus. In other words, the target is defined by :;:'_, user: it is the
biological structure for which effects of alpha paL'tic e radiation are
evaluated.
The effects of radiation begin at the subcellular level. Radiation
damage to tissues is considered significant if certain functional
capabilities or the viability of cells is affected. A wide variety or'
cytopathologic changes is possible in irradiated cells. Alpha particles
that intersect the cytoplasm without imparting ener_ to the nucleus
are usually not considered to be harmful to cell function and viability.
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However, ,.:ell death is likely if an alpha particle "hits" the nucleus, and
thus the nucleus is an excellent choice of a 'Itarget" for radiation dose
calculations. Diameters of cell nuclei in the body range from about
3 to 15 _m, depending on the cell type, the phase within the cell
cycle, and cell division. For some, the critical biological target is a 1-
_,m or smaller sphere within the nucleus containing the location of
double-strand DNA breaks after irradiation.
The exact mechanisms of radiation damage leading to different kinds
of cellular and subcellular effects are still being studied to determine
the relationship between the amount of energy imparted and the prob-
ability of those effects. For a given target, the radiation dose may be
determined if the distribution and number of alpha emitting sources
are known.
ABSORBED DOSE CALCULATIONS
The basic quantity describing the energy imparted to matter
is the absorbed dose. The absorbed or "average" dose is the mean
value of many energy deposition events in small targets. By definition,
the absorbed dose D is the quotient of d_" by d_, where d'e" is the
mean energy imparted by ionizing radiation to matter of mass d_ (12):
D = (4)
[The special name for the unit of absorbed dose is the gray (1 Gy =
1 J/kg), although many dosimetrists still prefer to use the term rad (1
rad = 0.01 J/kg)].
The absorbed dose rate (Gy/day) within a large, uniform
volume source is
D = CBE/m, (5)
where C is an energy conversion constant (0.512 g Gy/MeV _Ci day),
B is the activity of the alpha emitter (_Ci) in a volume of m (g), and
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E is the average energy (MEV) per disintegration, lt therefore follows
that the absorbed dose (Gy) from an internal emitter with a known
biological retention Ls
D = (01512 E f A o/m) ./_t B(t)dt (6)
where f is the fractional vield of alpha particles per radioactive deca,,',
A O is the initial activity (aCi). and B is the effective retention over
time c For a single exponential clearance and a known fraction
remaining at time t. the absorbed dose is
D = (-0.512 E f Ao t/m)[(1 _)/(In F)]. (7)
where F is the fraction of A o remaining at time t.
The approximate "average" dose to a microscopic target for
a single "random" traversal may be caiculated _', follows: Gi-'cn , 5.5
MeV alpha emitter, a target diameter of 8 _m. and a mean ch¢_rd
length of (2/3)'diameter = 5.33 /zm,
D(Gy) = "_im. (8)
,.,,'here "E= (5.33/31)(5.5 MeV) [.the ener_' imparted over the chorci].
= 0.77 MeV. or 1.23 x 10-6 er'g. and "
where m = d3/6rr _;cm 3 [mass = volume * density]
-10
= 2.68x 10 _. Therefore.
DIGvt 1.23 x l0 "6 erz,'(2.6S x 10"10= ,')(I0() rad Gv'l
= 0.46i Gr.
The actual dose to the target ,.,ill depend on the ox;tct chc_rct Icn,_th
,,,k,-n hv the ainha particle and the actual amount of cncr,,v dcpo._itcd.




will usually depend on the geometrical relationship between the spatial
distribution of alpha emitting sources and the spatial distribution of
targets.
Conventional dose-averaging neglects the stochastic variations in dose
at the microscopic level due to track-structure detail, target size. chord
length through the target, and relative specific ionizati¢)n with distance
traveled. Microdosimetry. however, takes these into account.
M]CRODOSIMETRY CALCULATIONS
Concepts of internal microdosimetry were developed t_vRoesch (13)
from the theory and quantitative formulations of Rossi (14.15).
Kellerer (16). and others. Simply stated, microdosimetry is a statistical
analysis of the probability of small targets receiving any possible radia-
tion dose.
Since each target (for example, a cell nucleus) receives a unique.
dose depending on the exact chord length for each alpha particle "hit,"
the number of hits. and the total amount of ener_: deposited, a
probability histogram may be constructed indicating the relative
frequency of any such dose.
The exact amount of enerm,, imparted to a microscopic target is the
specific enerD' (z). It is defined as the quotient ore by' m. where c
is the energy impart_zd by ionizing radiation to a small target hw,'ing
mass m;
Z = e/m (9)
The specific ener_ may be due to one or more energy-deposition
events. The possible values of the specific ener_, are described by a
probability density, ffz). The mean specific ener_, is the ahsc_rbcd
dose. D. and has the same unils as the absorbed dose:
2 = D (li))
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The probability density also includes the probability that no energy
is deposited in a site, or z = 0. This component, called the delta
function (6), is the fraction of unirradiated sites.
6 = exp(-M), or (11)
M = -In (5 , (12)
where M is she mean number of "hits" per target. The delta function
can be a useful parameter foi interpreting microdosimetry, distributions
for radiobiological experiments.
Tile lineal energy, or event size (y) is the quotient of e by T, where
e is the energy imparted to matter in a microscopic volume of interest
by an alpha particle interaction, and T is the mean chord length in
that volume resulting from random straight-line traversals oi" the
volume:
y = efr (13)
If that volume is a sphere with diameter d, then the mean chord
length is
T = 2dl3, and . (14)
y = 3e/2d. (15)
Lineal ener_ is a stochastic quantity subject to a geometric cut-off
rather than an energy cut-off. For spherical targets, lineal energy and
specific ener_, due to a single ener_' deposition event arc related by
the equation
z = (4/f,S)y (161)
wherep is the density of matter in the volume, and S is the surface
a,ea of the target. The mean lineal energ, y is similar in concept to thc
LET and has the same dimensions and units.
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The concepts of specific energy and lineal energy form the l'ound_-
tion of stochastic microdosimetry. Microdosimetry involves the calcul_k-
tion or experimental determination of probability densities in specific
energy for various types of radiation and various sizes of the t_rgct.
The probability density corresponds to the distributiot, of doses actu_ll-
ly received by cells or cell nuclei in a biological system and includcs
the probability that such targets are not irradiated. The c_icul_tit_ns
are complex and must be performed using computer techniques.
CALCULATION OF SPECIFIC ENERGY DISTRIBUTIONS
Probability densities in specific energy may be c_licul_lted using the
mathematical methods of Roesch (13). The spati_li distribution c_l"
alpha emitting sources is t]rst del]ned. The probability density is
calculated for a point source at any distance from a cell nucleus or
other specified target. The probability is then determined from thc
spatial distribution of sources that a point source exists at any given
distance from the target. The densities from all point sources are then
convoluted using Fourier transforms to construct a new specific ener_
density for the target population. Ali possible angles of intcrsection
and the relative specific ionization per unit length must be takcn into
account. The low-energy contributions of delta-ray electrons must also
be accounted for.
An example of a probability density in specific ener_,3' is shown in
Figure 3. This figure is a histogram of doses to cells exposed to _l
certain activity concentration of the alpha emitter americium-241 in
culture medium for about 5 hours, where the average dose is abt_ut
0.7 Gy and 22% of the targets receive no dose (the delta function).
The shape of the curve and the relative values of the close distributit_n
give information about the probable effectiveness of the irradi_ttion tc_
produce biological effects. Many aspects of the relationship betwecn
the probability density in specific energy and associ_ltect bic)lc_gic:_l
effects remain to be determined.




alpha emitting source incorrectly assume that the ionization field
within alpha particle range of the source is uniform at each distance
for which the absorbed dose is estimated. Such methods do not pro-
vide probability densities in specific energy, delta functions, or hit
probability and should not be used for evaluating the biological
effectiveness of alpha emitters on microscopic targets.
i i ,, ,,, i i li ,,
ooo f& ABSORBED DOSE =70 RADSW.->-p- 0.006
"_ 8 = 0.22ILl
>" 0.004
-J
8 pm TARGET (CELL)
<
o °°°2T' _', , l,I 1..... l,, , I 2, ,
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SPECIFIC ENERGYz (RADS)
FIGURE 3. End-product of a microdosimetry calculation' example
of probability density in specific ener_ for uniformly distributed
americium-241 source in unit-density medium containing S-tzm-diameter
targets. Delta function (6) is fraction of sites with no energy
deposition.
WHEN IS MICRODOSIMETRY TO BE APPLIED'?
Microdosimetr2,' is a statistical analvsis of the relative frequency ()f






from one target to another becomes smaller with increasing target
diameter and increasing absorbed dose. The variation increases with
smaller targets and lower absorbed doses. If the mean deviation or'
the specific energy from the absorbed dose exceeds about 0.2, then the
stochastic variability of the dose should be considered. Microdosimetry.
should generally be applied for studies evaluating radiobiological
effects on targets having diameters less than 100 _m and tbr absorbed
doses less than 10 Gy.
RELEVANCE OF ALPHA-PARTICLE DOSIMETRY TO
RADIOIMMUNOTHERAP Y
The objective of radioimmunotherapy is to employ an antibody
specifically directed against selected tumor-associatcd antigens oi"
malignant cells, couple a radionuclide to the antibody, and administer
the complex to a cancer patient. If the irnmunoconjugate binds to the
membrane of a cancer cell, the probability is good that the radiation
emitted will hit the cell nucleus. Multiple antibody/radionuclide
conjugates per targeted tumor cell should be sufficient for complete
cell killing and destruction of tumors or metastases. Reduced con-
centrations of radiolabeled antibody in normal tissues allow t'or tissue
sparing.
Alpha emitters should be particularly effe_.tive in cell killing anti
sparing of normal tissues due to their short range and high LET.
Alpha emitters previously considered for radioimmunotherapy include
astatine-211, bismuth-212, actinium-225 and radium-223. Actinium-
225 and radium-223 each emit four alpha particles bv their decay and
the decay of short-lived daughter products, greatly increasing their
potential antitumor effectiveness per unit activity administered.
Microdosimetric evaluations of the potential for alpha emitters in
radioimmunotherapy have been performed t'or bismuth-212 (17)and
for astatine-211 (9).
The absorbed dose to a tumor containing an alpha emitting irnmuno-
conjugate is an important parameter for comparing the relative
209
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effectiveness of different levels or concentrations of activity over time.
In practice it will not be possible to determine the probability density
in specific energy to a tumor or normal tissue unless tissue specimens
are examined autoradiographically and many complex calculations are
performed. Microdosimetry calculations can be Farticularlv valuable,
however, for unraveling the complicated dose-response relationships in
carefully controlled irradiations of mammalian cells in vitro. Micro-
dosimetry is a tool for interpreting the radiobiology and riot for
routine clinical dosimetry calculations.
0o010 I
F
0.000 | 1 _ I I
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FIGURE 4. Probability density in specific ener_ for alpha particle
emitted from surface of cell membrane. Prevalence of low-energy
contributions to cell dose is shown.
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Because radioimmunoconjugates bind to antigen sites on cell mem-
branes, the probability density in specific energy will shift to the lel't.
meaning that the relative number of biological targets (or cell nuclei)
receiving lower radiation doses will increase. This effect is shown in
Figure 4. When the alpha particle originates from the cell membrane,
there is both an increased probability of an energy deposition event
in the cell nucleus and increased probability that the total dose to the
target will be less than in the case where the sources are uniformly
distributed in the medium (compare the shape of the curve to the one
in Fig. 3). High doses mean that much energy is wasted in "over-kill"
and that the effect is not necessarily increased with increasing dose.
Alpha labeled immunoconjugates should therefore be highly effective
as antitumor agents because the alpha energy is more judiciously
utilized, and the probability of hitting the nucleus with sufficient
energy to kill the cell may be optimized with greater sparing of normal
tissue.
SUM2vIARY
Alpha emitters have current applications in medicine, particularly in
radioimmunotherapy. To be effectively used, however, the radiation
dosimetry must be well characterized at the cellular level. This
characterization requires analysis of the probability density in specific
energy imparted to microscopic targets of biological importance to
both cell killing and other nonlethal endpoints. The critical target
for microdosimetry calculations and internal alpha emitters should bc
the cell nucleus. The spatial distributions of both the alpha emitting
sources and the target cell nuclei must be determined to calculate
probability densities in specific ener_. The shape of the probability
density curve relates to the biological effectiveness of the irradiation.
The absorbed (average) dose is an important parameter that may be
correlated with biological effectiveness as long as the spatial
distributions of alpha sources and biological taroets remain constant
(18). When these spatial distributions change, however, the biological
effectiveness of the alpha emitter may also be expected to var;,,. Other
important parameters for evaluating the effectiveness or" internal alpha
211
emitters ?are the delta function (fraction of biological targets complete.
ly missed) and the probabilities of 1, 2, 3 ... n number of hits.
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